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Introduction 
Visceral mast cell tumours (MCTs) are much more common in cats than in dogs, with more 
than 50% of cases occurring in extracutaneous sites, and account for 15–26% of feline splenic 
disease. (Spangler and Culbertson, 1992; Henry and Herrera, 2013) 
Cats with splenic mast cell tumours (SMCTs) may have signs of systemic illness, including 
lethargy, anorexia, weight loss, and intermittent vomiting. Palpation of the abdomen reveals 
massive splenomegaly in most affected cats and, occasionally, peritoneal effusion. (Liska et 
al., 1979; Withrow, 2013; Henry and Herrera, 2013)  
One third of cats with SMCT are anaemic, and up to 50% have evidence of bone marrow and 
peripheral blood involvement. (Carpenter, 1987; Withrow, 2013) Metastatic spread to the 
liver is also frequent. (Henry and Herrera, 2013) 
Furthermore, the coexistence of splenic and cutaneous disease has been increasingly reported, 
especially in cats presenting with multiple skin lesions, and it is not clear in those cases which 
primary form of the tumour is more prevalent. (Litster and Sorenmo, Henry and Herrera, 
2013) Some authors have hypothesised an origin of feline visceral MCT from haematopoietic 
cell precursors, supporting a multicentre, “liquid” growth. (Garner and Ligeman, 1970) 
Splenectomy is the treatment of choice, even in the presence of multi-organic disease, 
resulting in a reported median survival time of 19 months. (Liska et al., 1979; Henry and 
Herrera, 2013) The role of chemotherapy for the adjuvant treatment of feline MCT has not 
been clearly established. Similarly, there is no proven utility for corticosteroid administration. 
(Henry and Herrera, 2013) 
The c-KIT proto-oncogene encodes the tyrosine kinase receptor Kit, which regulates mast cell 
survival, proliferation, differentiation, and migration. (Columbo et al., 1992; Meininger et al., 
1992) In canine MCT, juxtamembrane domain c-KIT mutations and aberrant cytoplasmic Kit 
protein localization have been associated with increased cellular proliferation and with both 
reduced progression-free and overall survival. (Webster et al., 2006; Webster et al., 2007) 
Consequently, Kit receptor tyrosine kinase inhibitors (TKIs) have entered as an active part of 
MCT treatment in dogs. (Hahn et al., 2008; London et al., 2009) 
Aberrant cytoplasmic Kit immunohistochemical expression has been reported in 29% to 67% 
of feline cutaneous MCTs, and a higher frequency was observed in tumours with 
unfavourable outcome. (Rodriguez-Cariño et al., 2009; Sabattini et al., 2010; Mallett et al., 
2013) Furthermore, between 62% and 68% harbour c-KIT mutations in exons 8 and 9, and 
there are anecdotal reports of beneficial response to molecular targeted therapy.
 
(Isotani et al., 
2009; Sabattini et al., 2013) These findings suggest that TKIs may offer a new treatment 
avenue for selected cases of feline mast cell neoplasia. 
In a report by Dank et al. (2002) no KIT mutation was identified in 10 cats with splenic MCT; 
(Dank et al., 2002) however, exons 8 and 9 had not been investigated in that study and, since 
then, no specific research has been carried out to assess the true frequency of Kit receptor 
dysregulations in feline splenic MCTs. A better understanding of the role that Kit plays in the 
development of feline SMCTs may possibly provide help in the clinical approach and 
treatment of this disease. 
The present study was aimed at characterizing Kit receptor dysregulations (i.e., cytoplasmic 
immunohistochemical expression and/or c-Kit mutations) in a series of feline splenic mast cell 
tumours. Specifically, our goals were: (1) to assess whether aberrant cytoplasmic expression 
of Kit could be regarded as indicative of c-KIT mutations, and (2) to evaluate the relationship 
between Kit dysregulation and tumour morphology, proliferation, and overall survival. 
Materials and Methods 
Inclusion criteria and histological parameters 
Formalin-fixed and paraffin-embedded (FFPE) surgical samples of feline splenic mast cell 
tumours were retrieved from the archives of the Department of Veterinary Medical Sciences 
(University of Bologna, Italy) and Laboratoire IDEXX Alfort (Alfortville, France). Four 
micrometers histological sections stained with haematoxylin and eosin were reviewed and a 
metachromatic stain (toluidine blue) was applied in all cases to confirm the diagnosis and to 
evaluate the amount of cytoplasmic granules. Table 1 summarizes the quantitative and 
qualitative histological parameters evaluated. 
Immunohistochemical analysis 
Kit protein expression pattern was evaluated immunohistochemically. Tumour sections were 
immunolabelled by using a commercial anti-human antibody (CD117, rabbit polyclonal, 
Dako, Glostrup, Denmark) with validated reactivity in feline tissues. (Sabattini et al., 2013; 
Sabattini et al., 2015)  
Endogenous peroxidase activity was blocked by incubation for 30 mins with 3% hydrogen 
peroxide in distilled water. For antigen retrieval, slides were microwaved in citrate buffer (pH 
6.0), for two cycles of 5 mins, at 750 W. Following incubation in a blocking solution (10% 
goat serum) for 30 minutes at room temperature, slides were incubated overnight at 4°C in a 
humid chamber with the primary antibody; CD117 was diluted 1:100 in phosphate-buffered 
saline. 
Sites of primary antibody binding were identified using a secondary biotinylated antibody 
(1:200 in blocking solution, Dako) for 30 minutes at room temperature. Sections were then 
incubated with a commercial streptavidin-biotin-peroxidase kit (Vectastain Elite ABC Kit, 
Vector Laboratories, Burlingame, California, USA) and 3,3’-diaminobenzidine (DAB tablets, 
Diagnostic BioSystems, Pleasanton, California, USA) was used as chromogen. Sections were 
counterstained with Papanicolaou’s haematoxylin, dehydrated, and mounted.  
A feline cutaneous MCT was used as positive control. Negative controls were obtained by 
omitting the primary antibody. Table 1 reports the methods for the evaluation of 
immunopositivity. 
Mutation analysis 
Genomic DNA was purified from 10 µm sections (3 to 5) of FFPE tumour samples by using a 
commercial kit (AllPrep DNA/RNA FFPE kit, Qiagen, Hilden, Germany) following 
manufacturer’s instructions. The extracted DNA concentration and purity were measured 
using Nanodrop ND-1000 spectrophotometer. 
The entire sequence of exons 8, 9, 11 and 17 of feline KIT were PCR amplified using the 
oligonucleotides already described.(Isotani et al., 2010) Furthermore, for exons 8 and 9, 
whenever the full length amplicon could not be obtained using those primers, the target was 
amplified using different combinations of the same outer and novel inner primers, as 
schematically indicated in Figure 1. Detailed primer sequence is reported in Table 2.  
Two microliters of diluted DNA (up to 50 ng/µl) were used as a template for the PCR 
amplification. Reactions were carried out in a T-Personal thermocycler (Biometra GmbH, 
Göttingen, Germania) by using 0.5 µM of each primer (Tema Ricerca, Castenaso, Italy), 0.02 
U/µl of Q5 High Fidelity DNA polymerase (EuroClone, Pero, Italy), 200 μM 
deoxyribonucleotide triphosphate mix and 1× Q5 buffer (final concentrations). The following 
PCR conditions were used: an activation step at 98°C for 45 s, 35 cycles of 15 s at 98°C, 15 s 
(exons 8 and 9 shorter fragments) or 30 s (full length amplicons) at 56°C (full length exons 9, 
11, 17) or 58°C (for all the remaining amplicons), 20 or 40 s at 72°C (for exons 8 and 9 
shorter fragments and full length amplicons, respectively), and a final extension step of 2 
mins at 72°C. Amplicons were visualized in a 1% agarose gel electrophoresis. All the PCR 
products were sequenced on an automated sequencer by BMR Genomics (Padua, Italy) and 
Macrogen Europe (Amsterdam, The Netherlands). Amplicons were sequenced starting from 
both forward and reverse primers used for the PCR amplification and from at least two 
different PCR products.  
Obtained electropherograms were analyzed by FinchTV tool (Geospiza, Seattle, WA, USA). 
The alignment of the wild type sequence available in the database Ensembl Genome Browser 
with sequences obtained in this study was performed using Multalin interface page 
(http://multalin.toulouse.inra.fr/multalin/). 
Medical records 
Patient records were reviewed to collect demographic information. 
Referring veterinarians and/or owners were contacted for additional information, including 
history, clinical stage, laboratory findings, ultrasound/surgical findings, treatment details and 
outcome. The availability of these data was not considered among inclusion criteria. 
Statistical analysis 
When appropriate, data sets were tested for normality by use of the D’Agostino and Pearson 
omnibus normality test. Values were expressed as mean ± standard deviation in case of 
normal distribution, or as median with a range in case of non-normal distribution. Differences 
in qualitative and quantitative variables were assessed by Fisher’s exact test and analysis of 
variance, respectively. 
Overall survival (OS) was defined as the time (days) from the date of diagnosis to the last 
reported date that the patient was seen alive. The patient status was recorded as alive, dead 
because of non MCT-related causes or dead because of MCT-related causes. The log-rank test 
was used to compare survival distributions.  
Data were analysed by use of a commercial software program (SPSS Statistics v 19, IBM); P 
values ≤ 0.05 were considered significant.  
Results 
Medical records 
Twenty-two cats with a histologically confirmed splenic mast cell tumour were included in 
the study. There were 21 domestic shorthair and one domestic longhair. Age ranged from 6 to 
16 years, with a mean of 11.6 ± 2.42 years. There were 8 males (36.4%) and 14 females 
(66.7%). Vomiting, dysorexia and weight loss were the most common clinical signs at 
presentation. Four patients had liver metastases. Mastocytemia was investigated in only 5 
cases and was reported in 2. Bone marrow cytology, performed in 3 cases, was positive for 
MCT infiltration in 2. Two cats had also a single cutaneous nodule at presentation and four 
later developed disseminated cutaneous MCTs.  
One cat with massive neoplastic diffusion was euthanized immediately following diagnosis, 
one cat only received corticosteroids. The remaining 20 underwent splenectomy: 12 were 
treated with splenectomy alone, 7 received adjuvant corticosteroids, and one cat received 
adjuvant lomustine and a tyrosine kinase inhibitor (imatinib). 
Follow-up information was available in 16 cases. Median survival time was overall 780 days 
(range, 1-1219). The presence of an exclusive splenic involvement (negative staging) was 
significantly (P = 0.042) associated with longer survival times (807 days versus 120 days). 
There was no significant difference between cats treated with surgery alone or surgery plus 
medical therapy. 
Histological examination 
In 18 cases (81.8%) the mastocytic infiltrate was diffuse, whereas 4 MCTs (18.2%) showed a 
lower cellularity and splenic infiltration was multifocal. 
Eight tumours (36.4%) were classified as well-differentiated and were composed by sheets of 
round to oval cells, 10-15 µm in diameter, with distinct cell borders. Cytoplasms were 
moderate to abundant, faintly granular, basophilic or pale eosinophilic. Nuclei were round to 
oval, with finely dispersed chromatin and inconspicuous nucleoli. The size of cells and nuclei 
within the neoplasm was rather uniform (variations < 50%). (Figure 1). 
Nine tumours (40.9%) were classified as moderately differentiated and were characterized by 
sheets of cells, 15-20 µm in diameter, with mostly distinct cell borders and low amounts of 
eosinophilic cytoplasm. Nuclei were round or occasionally indented, with irregularly stippled 
chromatin and a small single central nucleolus visible in most cells. A variation of 50-100% 
in nuclear size was recorded (Figure 1). 
Five tumours (22.7%), classified as poorly differentiated, were composed by polygonal cells, 
15-20 µm in diameter, with mostly indistinct borders and scant, amphophilic cytoplasm. 
Nuclei were large, vesicular, often indented or bizarre, with prominent nucleoli. A variation of 
up to 100% in nuclear size was present (Figure 1). 
Mitotic index (MI) ranged from 0 to 6 (mean, 2.2 ± 1.94). MI was significantly higher in 
moderately or poorly differentiated SMCTs (mean MI, 2.8) compared with well-differentiated 
SMCTs (mean MI, 1.1; P = 0.05). 
Eosinophilic infiltrate was moderate to high in 2 cases (9.1%); in the remaining 20 cases 
(90.9%), eosinophils were low to absent. Necrosis was observed in 4 cases (18.2%). 
Cytoplasmic granules were evaluated with toluidine blue stain and rated low in 3 cases 
(13.6%), moderate in 8 (36.4%) and high in 11 (50%). There was no statistical relationship 
among histological parameters, nor between histopathological parameters and survival. 
Kit pattern 
Twenty-one cases were immunoreactive for Kit protein. Three tumours (14.3%) revealed a 
prevalent membranous expression (Kit pattern 1), 11 (52.4%) had a focal cytoplasmic 
expression (Kit pattern 2) and 7 (33.3%) a diffuse cytoplasmic expression (Kit pattern 3; 
Figure 2). There was no statistical relationship between Kit pattern and tumour differentiation, 
mitotic activity or survival. 
Mutation analysis 
Mutation analysis was carried out on all samples. In two cases (9.1%) amplification was not 
successful due to the poor quality of extracted DNA, so the following information will refer to 
a total of 20 cases. 
Missense mutations (altering the amino acid composition of Kit) were detected in 13 out of 20 
tumours (65%). Eleven (19%) were located in exon 8, and 3 (71%) in exon 9; one tumour had 
two concurrent mutations in exons 8 and 9. No mutations were detected in exons 11 and 17. 
The location of the observed mutations is illustrated in Figure 3. The mutations found in exon 
8 were three internal tandem duplications (ITD) and one deletion-insertion. Seven cases 
(35%) presented the same ITD, consisting in the duplication of amino acids in position 415-
418 and “QILT” insertion (c.1245_1256dup; p.418T_419H ins QILT). The other two ITDs, 
observed in 2 and one case, respectively, were c.1246_1257dup (p.419H_420E ins ILTH) and 
c.1247_1261dup (p.420E_421S ins ILTHE). The remaining mutation, resulting in the 
introduction of a stop codon (c.1254_1263 delinsGTAA), was observed in one case (Figure 
3).  
In exon 9, two types of single nucleotide polymorphisms (SNPs) were detected: c.1430 G>T 
(p.477S>I), occurring in two cases and c.1426 C>A (p.476Q>K), occurring in one case 
(Figure 3). Silent mutations were observed in other 3 cases. 
All the mutated tumours displayed an aberrant (focal or diffuse cytoplasmic) Kit pattern (P = 
0.031), but a cytoplasmic expression was also encountered in 4 out of 7 (57.1%) non mutated 
tumours. 
The mutational status was not apparently associated with tumour morphology or mitotic 
activity. There were no significant differences in survival time between mutated or non 
mutated SMCTs, nor between tumours harbouring an exon 8 ITD and the other cases (Table 
2). 
Discussion 
The goal of this study was to investigate the nature and incidence of Kit dysregulations in 
feline splenic mast cell tumours. 
Given the infrequency of this disease, the analysis was performed on a relatively small 
number of cases, which may have resulted in loss of statistical power. The retrospective 
nature of the study is a further limitation, as cases lacked uniformity in staging and therapy 
protocols. 
We confirm a greater frequency of this disease in geriatric patients, with an age of onset 
(mean, 12 years) of some years higher than that of cutaneous MCT (mean, 8-9 years), and a 
clinical presentation characterized by nonspecific gastrointestinal symptoms, with the 
exception of the presence, in several patients, of a palpable abdominal mass. In more than 
20% of cases there were concurrent skin nodules. In no case, however, it was possible to 
establish with certainty the primitive location. 
Compared with dogs, in feline MCT staging procedures are far less consolidated. This is 
probably due to the lower frequency of MCT in cats and to the fact that the biological 
behaviour of these tumours is considered less aggressive. While this is generally true for the 
localized cutaneous forms, it does not apply to visceral MCTs or systemic mastocytosis; in 
these cases, accurate staging and close monitoring can drastically affect prognosis. In fact, the 
presence of a disease limited to the spleen was the only factor significantly affecting survival 
in this study.  
At present, there are no available studies describing the histological features of FSMCT. The 
observation of our cases has not led to the identification of histological types similar to those 
reported in cutaneous MCTs. The evidence, in a limited number of cases, of a multifocal 
pattern, as opposed to the more frequent diffuse pattern, would likely be attributable to an 
early stage neoplastic infiltration. Nevertheless, we have identified different degrees of 
differentiation and, as previosuly observed in cutaneous and intestinal MCTs, a poor cell 
differentiation appears to match a high mitotic activity, the only recognized histological 
prognostic factor in feline MCT. (Sabattini et al., 2013; Sabattini et al., 2015) It is important 
to point out that the attribution of the degree of differentiation was based in this study solely 
on the morphological appearance; the distribution and density of granules have been 
evaluated separately and were not correlated to the degree of differentiation. This also 
confirms previous studies on feline cutaneous and intestinal MCTs. (Sabattini et al., 2013; 
Sabattini et al., 2015) 
So far, c-KIT mutations of have been detected with a frequency of 56% in cutaneous MCTs, 
whereas they have not been identified in intestinal MCTs. (Sabattini et al., 2013; Sabattini et 
al., 2015) Although studies have been published evaluating mutations in feline MCT with 
unspecified location, (Isotani et al., 2010) this is the first time that c-KIT mutation analysis is 
performed specifically on a cohort of FSMCT. 
One possible limitation derives from the fact that the starting material for mutational analysis 
were tissue samples fixed in formalin and embedded in paraffin. This can lead to an 
underestimation of the mutations due to the potential presence of PCR inhibitors (solvents, 
paraffin), or because of poor DNA quality (excessive fragmentation following formalin 
fixation). In order to improve the results of sequencing, for exons 8 and 9 we adopted the 
strategy of the amplification of shorter fragments,. When unsuccessful, the phases of 
extraction and amplification were repeated several times and it was ultimately possible to 
carry out mutation analysis in 20 cases out of 22. 
The mutations identified in this study are very similar for frequency and type to those 
previously reported in feline cutaneous MCTs. (Isotani et al., 2010; Sabattini et al., 2013) 
This can represent a further confirmation of the intimate connection between the splenic and 
cutaneous forms, as opposed to the intestinal form. All the mutations were located at the level 
of exons 8 and 9, corresponding to the fifth immunoglobulin-like domain (IgD5) of Kit 
receptor. As in cutaneous MCTs, two hot spots were identified at the level of residues 415-
421 (exon 8) and 476-477 (exon 9), but while in cutaneous MCTs exon 9 mutations clearly 
prevailed, mutations in SMCT seem to occur much more frequently at the level of exon 8. 
These mutations were located in a neighbouring residue of mutations that have been reported 
in patients with pediatric mastocytosis and have been uncommonly described in canine mast 
cell tumour. (Lanternier et al., 2008; Letard et al., 2008) Mutations at this level were 
considered to affect the affinity of the hemophilic dimerization of Kit, resulting in the 
constitutive activation of the kinase domain without ligand binding. In particular, the 
duplication c.1244_1255dup, consisting of the insertion of 4 amino acids (glutamine, 
isoleucine, leucine, and threonine) between residues 418 and 419, was the most frequent 
mutation observed in previous studies. (Hadzijusufovic et al., 2009; Isotani et al., 2010; 
Sabattini et al., 2013) The insertion reported here (AAATCCTGACTC) is shifted to a base 
compared with that previously reported (AATCCTGACTCA), but results in the same protein 
change.  
Exon 9 mutations were also previously reported and mutations at that level were 
demonstrated to cause ligand-independent activation of Kit. (Isotani et al., 2010; Takanosu et 
al., 2012) Mutations around this residue are not observed in human tumours; however, 
identical substitutions were reported on the corresponding codon of Ser479 in canine MCT as 
an activating mutation. (…) 
In the dog a good degree of correlation is observed between the presence of genomic 
mutations and aberrant protein localization, although mutational analysis remains the gold 
standard for the selection of candidates for targeted therapies. Previous studies on feline 
cutaneous MCT failed to demonstrate a statistically significant association between the 
presence of mutations and Kit pattern. (Sabattini et al., 2013) In this study, the association 
was statistically significant, although we observed a very short incidence of membranous 
pattern compared with the aberrant pattern, even in non-mutated cases, so we can conclude 
that immunohistochemistry cannot be considered as a surrogate marker for mutation analysis 
in feline MCTs. Moreover, as in the previous studies, we did not evidence a correlation 
between mutations and survival time, mitotic activity or degree of differentiation; suggesting 
a secondary role of c-KIT mutations in affecting tumour biological behaviour As a possible 
explanation, these mutations may simply reflect a genomic instability (passenger mutations) 
and do not provide any substantial advantage to the neoplastic population. 
In conclusion, mutations of KIT are present in more than 60% of feline splenic MCTs and are 
mostly represented by internal tandem duplications at the level of exon 8. However, their 
assessment for prognostic purposes appears to be of limited value in this species.  
The predictive role of Kit receptor remains to be investigated by evaluating the response to 
tyrosine kinase inhibitors of FSMCT in relation to the mutational status. 
 
References 
Figure legends 
Figure 1. Feline splenic mast cell tumour (FSMCT), representative examples of tumour 
degree of differentiation. (A) Well differentiated FSMCT, (B) moderately differentiated 
FSMCT and (C) poorly differentiated FSMCT. Haematoxylin and eosin; x400 magnification. 
Figure 2. Photomicrographs of the different patterns of Kit immunostaining. (A) Kit pattern 
1, (B) Kit pattern 2 and (C) Kit pattern 3. CD117 immunohistochemistry; haematoxylin 
counterstain; x1000 magnification. 
Figure 3. Alterations in the nucleotidic and aminoacidic sequences of feline c-kit (exons 8 
and 9) observed in 20 splenic mast cell tumours. 
